First human tests begin for new drug candidate

NCT ID NCT07471932

Recruiting now Knowledge-focused Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

Summary

This is an early safety study testing a new drug called LAD106 in healthy volunteers. The main goal is to see how safe the drug is, how the body processes it, and what side effects might occur. Researchers will test different single and multiple doses in small groups of healthy adults to gather initial data before testing in patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Centre for Human Drug Research (CHDR) Phase 1 Unit
RECRUITING

Leiden, Netherlands

Conditions

Explore the condition pages connected to this study.

HEALTHY VOLUNTEERS